Drugs / Ketoprofen
Ketoprofen
also known as
IDEA-033 · Diractin · KTP · RP19583 · (rs)-ketoprofen · 19583RP · Actron · Actron ketoprofen · +44 more
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | ORUDIS | — | 1987-07-31 – 1994-01-06 | fda.gov ↗ |
| Approved | US (FDA) | ORUDIS | — | 1986-01-09 | fda.gov ↗ |
Trials 55
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03514810 | Jan → Sep 2017 | major depressive disorder | Kufa University | Completed | No outcome recorded |
| Phase 1 | NCT01020279 | Oct 2009 → Jan 2010 | musculoskeletal system disorder | X-pert Med GmbH | Completed | No outcome recorded |
| Phase 1 | NCT00745264 | Oct 2007 → Mar 2008 | — | IDEA AG | Completed | No outcome recorded |
| Phase 211 trials · 1 missed | ||||||
| Phase 2 | NCT06912763 | Aug 2025 → Mar 2031 expected | head and neck cancer, lymphedema | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06731647 | Feb 2025 → Nov 2027 expected | pneumothorax | Centre Hospitalier Universitaire, Amiens | Recruiting | No outcome recorded |
| Phase 2 | NCT05062083 | Jun 2022 → Sep 2023 | multiple sclerosis | National Institute of Mental Health (NIMH) | Terminated | No outcome recorded |
| Phase 2 | NCT02439034 | Feb 2015 → Sep 2016 | cervical cancer, upper aerodigestive tract neoplasm | Centre Oscar Lambret | Completed | No outcome recorded |
| Phase 2 | NCT02180087 | Feb 2014 → Aug 2015 | — | University Hospital, Clermont-Ferrand | Unknown | Missed primary |
| Phase 2 | NCT00647231 | Mar → Aug 2008 | osteoarthritis, knee | Hisamitsu Pharmaceutical Co., Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00903994 | Jun → Aug 2007 | tendinitis | APR Applied Pharma Research s.a. | Completed | No outcome recorded |
| Phase 2 | NCT00265304 | Jul 2005 → Jul 2007 | osteoarthritis, knee | IDEA AG | Completed | No outcome recorded |
| Phase 2 | NCT00211549 | Jun 2005 → ? | osteoarthritis, knee | IDEA AG | Completed | No outcome recorded |
| Phase 2 | NCT00108810 | Apr → Oct 2005 | osteoarthritis, knee | ZARS Pharma Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00317733 | ? → Jan 2004 | osteoarthritis, knee | IDEA AG | Completed | No outcome recorded |
| Phase 2/32 trials · 1 missed | ||||||
| Phase 2/3 | NCT03199417 | May 2017 → May 2018 | osteoarthritis, knee | University of Michigan | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2/3 | NCT02099006 | Nov 2013 → Jun 2015 | female reproductive system disorder | University of Rochester | Completed | Missed primary |
| Phase 324 trials · 1 met primary · 2 missed | ||||||
| Phase 3 | NCT06202989 | Sep 2024 → May 2026 | — | KAZM Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 3 | NCT06381063 | Mar 2024 → Mar 2027 expected | — | Centre Hospitalier Universitaire, Amiens | Recruiting | No outcome recorded |
| Phase 3 | NCT04421911 | Mar → Sep 2020 | osteoarthritis | Handok Inc. | Completed | No outcome recorded |
| Phase 3 | NCT03836807 | Apr → Jul 2018 | — | Dompé Farmaceutici S.p.A | Completed | Met primary |
| Phase 3 | NCT03025113 | Mar 2018 → Nov 2019 | musculoskeletal system disorder | EMS | Completed | No outcome recorded |
| Phase 3 | NCT02862977 | Nov 2017 → Jun 2019 | musculoskeletal system disorder | EMS | Completed | No outcome recorded |
| Phase 3 | NCT02905058 | Oct 2016 → May 2017 | — | Assiut University | Completed | No outcome recorded |
| Phase 3 | NCT01890902 | Aug 2013 → Jun 2014 | — | Imprimis Pharmaceuticals, Inc. | Withdrawn | No outcome recorded |
| Phase 3 | NCT00971581 | Aug 2009 → May 2010 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00929877 | Jun 2009 → Apr 2010 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00557544 | Jun → Dec 2009 | migraine disorder | IRCCS Burlo Garofolo | Withdrawn | No outcome recorded |
| Phase 3 | NCT00810121 | Nov 2008 → Jun 2009 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00722852 | Jun 2008 → Feb 2009 | osteoarthritis, knee | IDEA AG | Completed | Missed primary |
| Phase 3 | NCT00716547 | May 2008 → Mar 2009 | osteoarthritis, knee | IDEA AG | Completed | Missed primary |
| Phase 3 | NCT00680784 | Apr → Nov 2008 | — | Hisamitsu Pharmaceutical Co., Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00532038 | Sep 2007 → Nov 2008 | osteoarthritis | ZARS Pharma Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00792727 | Sep 2007 → Apr 2008 | osteoarthritis, knee | Hisamitsu Pharmaceutical Co., Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00488267 | Jun 2007 → Jun 2008 | osteoarthritis | ZARS Pharma Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00426985 | Feb 2007 → Mar 2008 | bursitis, tendinitis | Alkemira SA | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT00365586 | Aug 2006 → Apr 2007 | osteoarthritis | Alkemira SA | Completed | No outcome recorded |
| Phase 3 | NCT00352625 | Jun 2006 → Feb 2007 | bursitis, tendinitis | Alkemira SA | Completed | No outcome recorded |
| Phase 3 | NCT00351104 | Jun 2006 → Feb 2007 | — | Alkemira SA | Completed | No outcome recorded |
| Phase 3 | NCT00316784 | Jul 2005 → May 2006 | osteoarthritis, knee | IDEA AG | Completed | No outcome recorded |
| Phase 3 | NCT00372333 | Aug 2004 → Dec 2007 | arthropathy | IDEA AG | Completed | No outcome recorded |
| Phase 413 trials · 1 met primary | ||||||
| Phase 4 | NCT07826988 | Oct 2026 → Oct 2029 expected | sickle cell disease | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05761015 | Dec 2023 → Apr 2028 expected | chronic pain syndrome, osteoarthritis, hip, osteoarthritis, knee | University Hospital, Clermont-Ferrand | Recruiting | No outcome recorded |
| Phase 4 | NCT03911336 | Jan 2023 | tooth disorder | University of Iowa | Withdrawn | No outcome recorded |
| Phase 4 | NCT02619695 | Jun 2015 → Jan 2016 | — | Akdeniz University | Unknown | No outcome recorded |
| Phase 4 | NCT02491736 | Jun 2015 → Jan 2016 | tenosynovitis of foot and ankle | Akdeniz University | Unknown | No outcome recorded |
| Phase 4 | NCT02730026 | Jun 2015 → Dec 2016 | — | Luis Fernando Simoneti | Completed | No outcome recorded |
| Phase 4 | NCT02491879 | Jun 2015 → Jan 2016 | — | Akdeniz University | Unknown | No outcome recorded |
| Phase 4 | NCT02393846 | Feb → Jun 2015 | — | Akdeniz University | Completed | No outcome recorded |
| Phase 4 | NCT01882530 | Jul 2013 → Jan 2016 | — | Rennes University Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT01566253 | Mar → Dec 2012 | — | University Hospital, Montpellier | Completed | No outcome recorded |
| Phase 4 | NCT02257970 | Mar 2009 → Dec 2016 | lymphedema | Stanford University | Completed | Met primary |
| Phase 4 | NCT00799838 | Nov 2008 → Jun 2013 | upper respiratory tract disorder | Sanofi | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT02178293 | Sep 1998 → May 1999 | pharyngitis | Boehringer Ingelheim | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT00530387 | Jul 2008 → Jul 2011 | photoallergic dermatitis | NHS Tayside | Completed | No outcome recorded |
| — | NCT00188071 | Sep 2002 → Aug 2003 | — | University Hospital, Angers | Completed | No outcome recorded |
| Comparator or background therapy41 trials | ||||||
| Phase 1 | NCT07319728 Comparator | May 2025 → Jan 2026 overdue | osteoarthritis, knee | New Valley University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04802967 Comparator | Feb 2021 → Mar 2022 | — | Dompé Farmaceutici S.p.A | Completed | No outcome recorded |
| Phase 1 | NCT02156596 Comparator | Feb 2013 → Dec 2017 | urinary tract obstruction | University of Monastir | Completed | No outcome recorded |
| Phase 2 | NCT00745771 Comparator | Oct 2007 → Feb 2008 | — | IDEA AG | Completed | No outcome recorded |
| Phase 2/3 | NCT02538224 Comparator | Jul 2013 → Feb 2014 | chronic periodontitis | Islamic Azad University, Sanandaj | Completed | No outcome recorded |
| Phase 3 | NCT07108582 Comparator | Apr 2026 → Jul 2028 expected | chronic pain syndrome | University Hospital, Strasbourg, France | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT04726592 Background | Jul 2021 → Apr 2024 | migraine with aura, migraine without aura | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT04622813 Background | Apr 2021 → Oct 2022 | gallbladder disorder, neuropathy, painful, substance-related disorder | American University of Beirut Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT03585374 Comparator | Feb 2018 → Feb 2019 | — | Mundipharma Pharmaceuticals srl | Completed | Met primary |
| Phase 3 | NCT02905045 Comparator | Oct 2016 → Jul 2017 | — | Assiut University | Completed | No outcome recorded |
| Phase 3 | NCT02400047 Comparator | Jun 2015 → Jul 2019 | — | Rennes University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01228552 Comparator | Dec 2011 → Jan 2012 | migraine disorder | Behar, Caren, M.D. | Unknown | No outcome recorded |
| Phase 3 | NCT01211795 Comparator | Oct 2009 → Jun 2011 | migraine disorder | Behar, Caren, M.D. | Completed | No outcome recorded |
| Phase 3 | NCT00927641 Comparator | Jul 2009 → Nov 2010 | — | Hisamitsu Pharmaceutical Co., Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00765700 Comparator | Sep 2008 → Aug 2009 | — | Imprimis Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00679146 Comparator | Apr 2008 → Jun 2009 | — | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00680472 Comparator | Apr → Oct 2008 | — | Hisamitsu Pharmaceutical Co., Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01223053 Comparator | — | — | Imprimis Pharmaceuticals, Inc. | Withdrawn | No outcome recorded |
| Phase 4 | NCT07610265 Comparator | Apr 2024 → Oct 2025 | — | Nims University Rajasthan | Completed | No outcome recorded |
| Phase 4 | NCT07315698 Comparator | Nov 2020 → May 2023 | — | Indonesia University | Completed | No outcome recorded |
| Phase 4 | NCT03404908 Background | Feb 2018 → Jan 2019 | — | Medical University of Lublin | Completed | No outcome recorded |
| Phase 4 | NCT03244540 Background | Sep 2017 → Oct 2018 | neuropathy, painful | Medical University of Lublin | Completed | Met primary |
| Phase 4 | NCT02804126 Background | Jun 2017 → Jul 2018 | neuropathy, painful | Michał Borys | Completed | No outcome recorded |
| Phase 4 | NCT01685658 Comparator | Sep 2016 → Mar 2018 | urinary tract obstruction | Nîmes University Hospital | Withdrawn | No outcome recorded |
| Phase 4 | NCT02239497 Background | Mar → Sep 2013 | — | Hospital Central Dr. Luis Ortega | Completed | No outcome recorded |
| Phase 4 | NCT02638831 Comparator | Mar → Nov 2013 | osteoarthritis, knee | Dr. Reddy's Laboratories Limited | Completed | No outcome recorded |
| Phase 4 | NCT01816334 Comparator | Jan 2013 → Dec 2015 | sciatica | University Hospital, Grenoble | Completed | No outcome recorded |
| Phase 4 | NCT02248493 Background | Nov 2012 → Mar 2017 | neuropathy, painful | Lithuanian University of Health Sciences | Completed | No outcome recorded |
| Phase 4 | NCT02238340 Background | Mar → Aug 2012 | — | Hospital Central Dr. Luis Ortega | Completed | No outcome recorded |
| Phase 4 | NCT00553605 Comparator | Jun 2007 → Jun 2009 | — | Pfizer | Completed | No outcome recorded |
| — | NCT07853482 Background | Oct 2026 → May 2027 expected | — | Maternity Hospital - State Budgetary Institution of the Rostov Region, Taganrog | Not yet recruiting | No outcome recorded |
| — | NCT07059429 Comparator | Jul → Dec 2025 | — | State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia | Completed | No outcome recorded |
| — | NCT05840406 Background | Sep 2024 → Mar 2025 | — | University Hospital Sestre Milosrdnice | Completed | No outcome recorded |
| — | NCT07207304 Comparator | Feb 2022 → Mar 2023 | hepatocellular carcinoma | Iuliu Hatieganu University of Medicine and Pharmacy | Completed | No outcome recorded |
| — | NCT04500470 Background | Sep 2020 → Jul 2021 | female infertility | Aswan University Hospital | Completed | No outcome recorded |
| — | NCT05223946 Background | Sep 2020 → May 2021 | — | Kyrgyz State Medical Academy | Completed | No outcome recorded |
| — | NCT04172272 Comparator | Sep 2019 → Sep 2020 | chronic pain syndrome, endometriosis, leiomyoma, pelvic organ prolapse +1 | General Hospital Pula | Unknown | No outcome recorded |
| — | NCT04148846 Background | Sep 2019 → Sep 2020 | headache disorder | University of Sao Paulo General Hospital | Unknown | No outcome recorded |
| — | NCT02568644 Background | Jul → Oct 2014 | migraine disorder | Federal University of Minas Gerais | Completed | No outcome recorded |
| — | NCT02840526 Background | May 2013 → Dec 2014 | — | Silesian University of Medicine | Completed | No outcome recorded |
| — | NCT01734954 Background | Apr → Aug 2013 | — | CES University | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2013-02-19 | Harrow Inc | Results Imprimis Announces Successful Results from its Pharmacokinetic Study for its Impracor Topical NSAID harrow.com ↗
The application of an occlusive knee bandage with either heat or exercise following topical administration showed faster initial but lower overall plasma exposure of ketoprofen relative to non-occluded topical administration with no heat or exercise. |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-06-05 | Dompé Farmaceutici S.p.A | Project NeOn is underway. In Lombardy, the public and private sector have come together to meet the needs of those suffering from diseases of the nervous system and tumours with a high need for treatment. dompe.com ↗ |
| 2013-02-19 | Harrow Inc | Imprimis Announces Successful Results from its Pharmacokinetic Study for its Impracor Topical NSAID harrow.com ↗ |
| 2010-04-23 | Hisamitsu Pharmaceutical Co., Inc. | 「HKT-500」の米国での第Ⅲ相試験結果の件 hisamitsu.co.jp ↗ |
| 2006-08-24 | Hisamitsu Pharmaceutical Co., Inc. | 「HKT-500」の臨床開発(第Ⅲ相試験)結果の件 hisamitsu.co.jp ↗ |
Evidence & citations 55 cited values
Every value below carries the sentence it was read from. 99 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ketoprofen | “Thirty minutes before the end of surgery, nefopam 40 mg, paracetamol 1 g, and ketoprofen 100 mg will be administered intravenously, depending on the patient's comorbidities,...” NCT07207304 ↗92“Standard analgesia includes ketoprofen 100 mg twice daily and paracetamol 1000 mg every 8 hours for 24 hours after knee arthroplasty; morphine 10 mg IM as needed for rescue therapy.” NCT07059429 ↗ “Intraoperative administration intravenous of dipyrone 30-50 mg/Kg and or intravenous ketoprofen 100 mg or diclofenac 75 mg or ketorolac 30 mg” NCT01734954 ↗ “Multiprofen-CC™ is a multimodal topical cream including ingredients ketoprofen (10%), baclofen (5%), amitriptyline (2%), and lidocaine (5%).” NCT06202989 ↗ “Experimental - A multimodal topical cream treatment with Ketoprofen, Baclofen, Amitryptiline, and lidocaine in a carrier gel.” NCT03199417 ↗ “ketoprofen, tolperisone, symptomatic slow-acting drugs in osteoarthritis - SYSADOA - (glucosamine + chondroitin sulfate )” NCT05223946 ↗ “Each patient received one sachet that contained KLS 40 mg (equivalent to 25 mg of ketoprofen).” NCT03836807 ↗ “Both groups received intravenous analgesia with ketoprofen 100 mg regimen” NCT02239497 ↗ “2.5% ketoprofen gel (Fastjel) has been administer as 2 gr in 5 cm area.” NCT02619695 ↗ “Paracetamol 1 gram and ketoprofen 100 mg every 8 hours for 24 hours.” NCT04172272 ↗ “100 mg of ketoprofen in 50 ml volume given in 30 minutes by IV root” NCT02156596 ↗ |
| Known as | (rs)-ketoprofen | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | 19583RP | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | Actron | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | Actron ketoprofen | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | Alrheumat | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | Aneol | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | Artrosilene | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | Axorid | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | Capisten | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | Diractin | “Epicutaneously Applied Diractin® (Ketoprofen in Transfersome® Gel)” NCT00722852 ↗2“Epicutaneously Applied Diractin® (Ketoprofen in Transfersome® Gel)” NCT00716547 ↗ “100 mg ketoprofen from Diractin®” NCT00745264 ↗ |
| Known as | Fastjel | “2.5% ketoprofen gel (Fastjel) has been administer as 2 gr in 5 cm area.” NCT02619695 ↗ |
| Known as | Fenoket 200 | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | HKT-500 | “HKT-500 Ketoprofen Topical Patch” NCT00680784 ↗ |
| Known as | Hydratropic acid, m-benzoyl- | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | IDEA-033 | “A multicentre, randomized, placebo- and active-controlled trial comparing the efficacy and safety of topical ketoprofen in Transfersome gel (IDEA-033) with ketoprofen-free...” PMID 23542612 ↗ Mar 20135“Patients treated with IDEA-033 in Study 17-007 will receive 100 mg per knee of ketoprofen gel twice daily and one placebo capsule twice daily for 52 weeks.” NCT00265304 ↗ “100 mg ketoprofen in 4.4 g transfersome gel (IDEA-033) or 4.4 g ketoprofen-free vehicle (TDT 064) topically, twice daily, for 12 weeks.” PMID 23996292 ↗ Sep 2013 |
| Known as | Iso-k | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | Jomethid xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | Ketocid 200 | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | Ketonal | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | Ketoprofen l-lysinate | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | KETOPROFEN LYSINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | Ketoprofen Lysine Salt | “Ketoprofen Lysine Salt Combined with Gabapentin (KLS-GABA) Compared to Ketoprofen Lysine Salt (KLS) Alone in Healthy Male Subjects” NCT04802967 ↗ |
| Known as | KETOPROFEN SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | Ketoprofene | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | Ketoprofeno | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | Ketorin | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | Ketotard 200 xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | Ketovail | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | Ketozip 200 xl | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | KTP | “A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase III Study of the Efficacy, Tolerability and Safety of Ketoprofen Topical Patch, 20% (KTP) in the Treatment...” NCT00352625 ↗2“A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase III Study of the Efficacy, Tolerability and Safety of Ketoprofen Topical Patch, 20% (KTP) in the Treatment...” NCT00426985 ↗ “A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Phase III Study of the Efficacy, Tolerability and Safety of Ketoprofen Topical Patch, 20% (KTP) in the Treatment...” NCT00351104 ↗ |
| Known as | Larafen | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | Larafen cr | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | Medac ketoprofen | “Single injection of ketoprofen (Medac ketoprofen ® 100 mg/4 ml injection ampoule solution)” NCT02400047 ↗ |
| Known as | Nexcede | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | NSC-758144 | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | Orudis | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | Orudis 100 | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | Orudis kt | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | Oruvail | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | Oruvail 100 | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | Oruvail 150 | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | Oruvail 200 | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | Oruvail im | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | Powergel | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | RP19583 | “Drug: KETOPROFEN(RP19583)” NCT00929877 ↗1“KETOPROFEN(RP19583)” NCT06731647 ↗ |
| Known as | RU-4733 | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | Sector | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | Sodium ketoprofen | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | ThermoProfen | “ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System)” NCT00488267 ↗ |
| Known as | Tiloket | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | Tiloket cr | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Known as | Valket 200 retard | ChEMBL registry synonym — accepted as the source's own label CHEMBL571 ↗ |
| Modality | Small molecule | — CHEMBL571 ↗ |
| Route | Topical | “Patients assigned to IDEA-033 in Study 17-007 will topically apply 100 mg per knee of ketoprofen gel twice daily” NCT00265304 ↗ |